Childhood tuberculosis.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
pubmed:
11
8
2022
medline:
15
9
2022
entrez:
10
8
2022
Statut:
ppublish
Résumé
We discuss the most recent literature to support the identification of children at risk for tuberculosis and optimal testing and treatment strategies. The identification and management of children with tuberculosis has increased in complexity due to the recent severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) pandemic, greater use of immunosuppressive agents, and the administration of shorter, rifamycin-containing treatment regimens. Advancements in the diagnosis and treatment of tuberculosis in children include: use of interferon gamma release assays (IGRAs); molecular-based tests; and shorter courses of treatment. While the essential steps to identify and treat children at risk for tuberculosis remain unchanged, providers must be aware of impact of these challenges. The SARS-CoV-2 pandemic will likely have a negative impact on global tuberculosis control. It is important that countries maintain a comprehensive approach to the identification and management of children at risk for tuberculosis. Increasing evidence supports enhanced utilization of IGRAs and molecular-based testing to improve the diagnosis of tuberculosis in children. Shorter course, rifamycin-based treatment regimens are available to treat children with tuberculosis infection; however, their use is limited in some immunosuppressed children due to drug-drug interactions.
Identifiants
pubmed: 35947056
doi: 10.1097/QCO.0000000000000866
pii: 00001432-202210000-00016
doi:
Substances chimiques
Rifamycins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
477-483Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
World Health Organization. Global tuberculosis report 2021. [Internet]. Geneva, Switzerland: World Health Organization; 2021 [updated 2021 Oct 14; cited 2022 Feb 21]. Available from: who.int/publications/i/item/9789240037021
Centers for Disease Control and Prevention. Tuberculosis: Data and Statistics. [Internet]. Atlanta, Georgia, USA: Centers for Disease Control and Prevention; [updated 2022 Mar 24; cited 2022 Feb 21]. Available from: https://www.cdc.gov/tb/statistics/default.htm
Deutsch-Feldman M, Pratt RH, Price SF, et al. Tuberculosis – United States, 2020. MMWR Morbid Mortal Wkly Rep 2021; 70:409–414.
Bagcchi S. Dismal global tuberculosis situation due to COVID-19. Lancet Infect Dis 2021; 21:1636.
Centers for Disease Control and Prevention. Tuberculosis technical instructions for civil surgeons. [Internet]. Atlanta, Georgia, USA: Centers for Disease Control and Prevention; [updated 2019 Aug 19; cited 2021 Feb 21]. Available from: cdc.gov/tb/education/technical_inst.htm
American Academy of Pediatrics. Tuberculosis. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH. Editors. Red Book 2021 Report of the Committee on Infectious Diseases. Itasca, IL, USA: American Academy of Pediatrics; 2021. p. 786-814.
Nolt D, Starke JR. Tuberculosis infection in children and adolescents: testing and treatment. Pediatrics 2021; 148:e2021054663.
Wang Z, Posey DL, Brostrom RJ, et al. Postarrival evaluation of immigrant and refugee children in the USA with latent tuberculosis infection diagnosed overseas, 2007–2019. J Pediatr 2022; 245:149.e1–157.e1.
Alvarez GG, Sullivan K, Pease C, et al. Effect of implementation of a 12 dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: interrupted time series design. Int J Infect Dis 2022; 117:222–229.
Centers for Disease Control and Prevention. TB Centers of Excellence for Training, Education and Medical Consultation. [Internet]. Atlanta, Georgia, USA: Centers for Disease Control and Prevention; [updated 2018 Oct 2; cited 2022 Feb 14]. Available from: https://www.cdc.gov/tb/education/tb_coe/default.htm .
Fekadu G, Jiang X, Yao J, et al. Cost-effectiveness of video-observed therapy for ambulatory management of active tuberculosis during the COVID-19 pandemic in a high-income country. Int J Infect Dis 2021; 113:271–278.
Sekandi JN, Kasiita V, Onuooha NA, et al. Stakeholders’ perceptions of and barriers to using video-observed treatment for monitoring patients with tuberculosis in Uganda: exploratory qualitative study. JMIR Mhealth Uhealth 2021; 9:e27131.
Song R, Click ES, McCarthy KD, et al. Sensitive and feasible specimen collection and testing strategies for diagnosing tuberculosis in young children. JAMA Pediatr 2021; 175:e206069.
Kay AW, Gonzalez Fernandez L, Takwoingi Y, et al. Xpert MTB/RIF and Xpert MTB/RIF ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev 2020; 2020:CD013359.
World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection 2021 update. [Internet]. Geneva, Switzerland: World Health Organization; [updated 2021 Jul 7; cited 2022 Feb 14]. Available at: who.int/publications/i/item/9789240029415.
World Health Organization. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug Resistant Tuberculosis Treatment. [Internet]. Geneva, Switzerland: World Health Organization; [updated 2020 Jun 15; cited 2022 Feb 14]. Available from: who.int/publications/i/item/9789240007048.
Garcia-Prats AJ, Svensson EM, Winckler J, et al. Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. J Antimicrob Chemother 2021; 76:3237–3246.
Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med 2021; 386:911–922.
Pai M, Zar HJ. Childhood tuberculosis – time for shorter and differentiated treatment. N Engl J Med 2022; 386:988–989.
World Health Organization. SHINE trial on shorter treatment for children with minimal TB. [Internet]. Geneva, Switzerland: World Health Organization; [updated 2020 Oct 26; cited 2022 Feb 20]. Available from: who.int/news/item/26-10-2020-shine-trial-on-shorter-treatment-for-children-with-minimal-tb.